- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sanofi to collaborate with Regenoron for up to $2.17 billion for cancer drugs
Sanofi will collaborate with its long time partner to jointly develop a programmed cell death protein 1 (PD-1) as a part of phase 1 agreement, in the hot area of cancer immunotherapyFrench drugmaker Sanofi, has recently announced its $2.17 billion partnership with Regenoron Pharmaceutical to strengthen its focus on cancer immunotherapy. Sanofi has committed to make an upfront payment of...
French drugmaker Sanofi, has recently announced its $2.17 billion partnership with Regenoron Pharmaceutical to strengthen its focus on cancer immunotherapy. Sanofi has committed to make an upfront payment of $640 million to Regeneron. If all goes the ambitious way, the U.S. biotech company will get up to $375 million more if certain sales targets are a hit.
Sanofi will also invest more than $1 billion in research for the programme, which aims to tap the body's immune system to help fight cancer (as reported by Reuters).
As part of the agreement, the two companies will jointly develop a programmed cell death protein 1 (PD-1) inhibitor currently in Phase I clinical testing, and plan to start trials in 2016 with new drug candidates.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country.She is a member of the Association of Healthcare Journalists. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751